AbbVie Inc. (NYSE:ABBV) previous close was $104.74 while the outstanding shares total 1.77B. The firm has a beta of 0.82, a 12-month trailing P/E ratio of 23.45, and a growth ratio of 2.53. ABBV’s shares traded higher over the last trading session, gaining 2.43% on 12/04/20. The shares fell to a low of $105.02 before closing at $107.28. Intraday shares traded counted 7.05 million, which was 15.21% higher than its 30-day average trading volume of 8.31M. The stock’s Relative Strength Index (RSI) is 77.60, with weekly volatility at 1.89% and ATR at 2.43. The ABBV stock’s 52-week price range has touched low of $62.55 and a $106.38 high.
Investors have identified the Drug Manufacturers – General company AbbVie Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $184.92 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
AbbVie Inc. (ABBV) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For ABBV, the company has in raw cash 7.89 billion on their books with 4.78 billion currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on a decline. In terms of their assets, the company currently has 23009000000 million total, with 24181000000 million as their total liabilities.
ABBV were able to record 12.21 billion as free cash flow during the third quarter of the year, this saw their quarterly net cash flow reduce by -32.03 billion. In cash movements, the company had a total of 12.73 billion as operating cash flow.
Potential earnings growth for AbbVie Inc. (ABBV)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the third quarter of the year, AbbVie Inc. recorded a total of 12.9 billion in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 34.28% coming in sequential stages and their sales for the third quarter increasing by 19.2%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 5.05 billion trying to sell their products during the last quarter, with the result yielding a gross income of 7.85 billion. This allows shareholders to hold on to 1.77B with the revenue now reading 1.31 cents per share. This is a figure that is close to analyst’s prediction for their fourth quarter (2.75 cents a share).
Having a look at the company’s valuation, the company is expected to record 8.94 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on ABBV sounds very interesting.
Is the stock of ABBV attractive?
In related news, EVP, Chief HR Officer, RICHMOND TIMOTHY J. sold 51,990 shares of the company’s stock in a transaction that recorded on Nov 27. The sale was performed at an average price of 105.00, for a total value of 5,458,950. As the sale deal closes, the EVP, Chief Strategy Officer, Gosebruch Henry O now sold 40,000 shares of the company’s stock, valued at 3,975,046. Also, Vice Chairman, ALBAN CARLOS sold 115,830 shares of the company’s stock in a deal that was recorded on Nov 16. The shares were price at an average price of 100.00 per share, with a total market value of 11,583,000. Following this completion of acquisition, the Chairman of the Board and CEO, GONZALEZ RICHARD A now holds 194,154 shares of the company’s stock, valued at 18,851,790. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.10%.
14 out of 22 analysts covering the stock have rated it a Buy, while 6 have maintained a Hold recommendation on AbbVie Inc.. 0 analysts has assigned a Sell rating on the ABBV stock. The 12-month mean consensus price target for the company’s shares has been set at $112.05.